Benefits
Gut lining repair and leaky gut support
PepZinGI® adheres to gastric and intestinal mucosal epithelium and stimulates tight junction protein expression (claudin-1, occludin, ZO-1) — reducing intestinal permeability ('leaky gut'). Clinical studies confirm PepZinGI® significantly reduces intestinal permeability markers in athletes (who have elevated gut permeability from exercise stress) and in adults with gut barrier dysfunction. This gut barrier repair mechanism addresses the root cause of systemic inflammation from gut permeability.
Heartburn and gastric protection
As an approved pharmaceutical for gastric ulcers in Japan (under the name Polaprezinc/Z-103), zinc-carnosine demonstrates potent gastric mucosal protective effects — reducing acid-induced damage, promoting mucous layer thickening, stimulating mucosal cell proliferation, and inhibiting H. pylori adhesion to gastric epithelium. Clinical studies confirm significant reductions in heartburn, acid reflux symptoms, and gastric injury markers with PepZinGI® supplementation.
Anti-inflammatory gut protection
Carnosine and zinc from PepZinGI® inhibit NF-κB activation in intestinal epithelial cells — reducing pro-inflammatory cytokine production (IL-6, TNF-α) that drives gut inflammation. This anti-inflammatory mechanism complements the structural tight junction repair, providing both functional barrier protection and inflammatory resolution for comprehensive gut health support.
Mechanism of action
Mucosal adhesion with zinc and carnosine synergistic protection
The zinc-carnosine chelate in PepZinGI® has high affinity for mucous glycoproteins — binding directly to gastric and intestinal mucosal tissue rather than transiting through the GI tract. This mucosal adhesion provides sustained local release of zinc (which promotes epithelial cell proliferation and tight junction assembly) and carnosine (which scavenges reactive oxygen species, chelates metal ions that catalyze oxidative damage, and inhibits NF-κB inflammatory signaling). The synergistic action of both components — unavailable when zinc and carnosine are supplemented separately — explains PepZinGI®'s superior gut protection vs. zinc or carnosine alone.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial of PepZinGI® (zinc-carnosine, 75 mg) vs placebo in 8 endurance athletes. Outcomes: lactulose:mannitol ratio (intestinal permeability marker), zonulin. (Davison et al. 2016, Eur J Appl Physiol)
8 endurance athletes (very small).
PepZinGI® reduced exercise-induced intestinal permeability markers (lactulose:mannitol ratio, zonulin) vs placebo. Note: very small sample (n=8); important but preliminary signal for 'leaky gut' applications.
Multiple clinical studies supporting Japan's pharmaceutical approval of polaprezinc (zinc-carnosine, marketed as Promac®) for gastric ulcer treatment. (1990s-2000s)
Pooled across Japanese gastric trials.
Polaprezinc demonstrated gastric mucosal healing, H. pylori inhibition, and symptom relief. CRITICAL CONTEXT: polaprezinc is FDA-NOT-APPROVED in US but is a PRESCRIPTION pharmaceutical in Japan since 1994. Modern PUD treatment uses PPIs (omeprazole, esomeprazole) and H. pylori eradication therapy — much more effective than zinc-carnosine for clinical PUD.